ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0958

TCR Motifs Identify Unique Clones in African Americans with Systemic Sclerosis
Abstract Number: 1854

TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Autoimmune Diseases
Abstract Number: 2574

Tear Biomarkers for Monitoring Disease Activity and Progression of Noninfectious Chronic Anterior Uveitis in Children
Abstract Number: 1781

Tear Proteomics as a Classifier of Disease Type and Activity Status in Pediatric Uveitis
Abstract Number: 1950

Telehealth Physical Therapy Intervention to Increase Physical Activity in Adults with Knee OA: The Delaware PEAK Randomized Controlled Trial
Abstract Number: 1933

Telemedicine for Under-resourced Patients with Systemic Lupus Erythematosus: A Qualitative Study Exploring the Views and Experiences of Patients and Rheumatology Health Care Professionals
Abstract Number: 2539

Telocytes Integrated into Mast Cells and Joint-Draining Lymphatic Vessels Potentially Regulate Lymphatic Clearance
Abstract Number: 2343

Temporal Trends in and Associations with NSAID Prescription in Adult and Pediatric Patients with IBD
Abstract Number: 1397

Temporal Trends in Early Rheumatoid Arthritis (ERA) Patients with Moderate to Severe Disease Activity: A Multicenter Cohort Study of Treatment Strategies and Outcomes in Chinese Patients in the Modern Era
Abstract Number: 1595

Tezepelumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Abstract Number: 2595

TGF-β Activated Kinase 1 (TAK1) Inhibition Suppresses Synovial Inflammation and Tissue Destruction Mediated by Activated Juvenile Idiopathic Arthritis Synovial Fibroblasts
Abstract Number: 0920

TGF-β Activated Kinase 1 Inhibition by Pentagalloyl Glucose Inhibits NLRP3 Inflammasome Formation and Ameliorates MSU-Induced Inflammation
Abstract Number: 2301

The Added Value of anti-Ro52 Antibody Titer in the Diagnosis of Sjögren’s Disease
Abstract Number: 1237

The Art of Choosing Together: Unveiling the Patient’s Perspective in Rheumatology
Abstract Number: 0819

The Assessment of SpondyloArthritis International Society (ASAS) Definition of Difficult-to-Manage Axial Spondyloarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].